Spark Therapeutics (ONCE) trading of stock halted with FDA advisory committee review
Spark Therapeutics announced that NASDAQ has halted trading of its common stock. The FDA Advisory Committee is meeting to review LUXTURNA™ (voretigene neparvovec), an investigational, potential one-time gene therapy, for treatment of patients with vision loss due to biallelic RPE65-mediated IRD. October 12, 2017